Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) was the recipient of a significant decline in short interest in the month of October. As of October 30th, there was short interest totaling 8,974,834 shares, a decline of 46.2% from the October 15th total of 16,679,713 shares. Approximately 8.1% of the shares of the company are short sold. Based on an average daily trading volume, of 3,629,551 shares, the days-to-cover ratio is currently 2.5 days.
Analysts Set New Price Targets
A number of equities analysts have weighed in on the company. Wedbush restated an “outperform” rating and issued a $7.00 target price (down from $9.00) on shares of Perspective Therapeutics in a research note on Tuesday, November 10th. BMO Capital Markets reissued an “outperform” rating on shares of Perspective Therapeutics in a report on Friday, October 30th. William Blair began coverage on shares of Perspective Therapeutics in a research report on Friday, September 18th. They issued an “outperform” rating on the stock. Bank of America lowered their target price on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research note on Friday, August 14th. Finally, BTIG Research reissued a “buy” rating on shares of Perspective Therapeutics in a research note on Monday, October 26th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $10.10.
Get Our Latest Analysis on CATX
Perspective Therapeutics Stock Performance
Shares of CATX stock traded down $0.01 during trading hours on Monday, hitting $0.94. 2,013,385 shares of the company’s stock were exchanged, compared to its average volume of 2,411,416. Perspective Therapeutics has a 12-month low of $0.78 and a 12-month high of $6.16. The business’s 50 day simple moving average is $2.11 and its 200-day simple moving average is $3.44. The company has a current ratio of 5.18, a quick ratio of 5.18 and a debt-to-equity ratio of 0.01.
Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.06 million. Perspective Therapeutics had a negative net margin of 55,866.82% and a negative return on equity of 42.25%. As a group, sell-side analysts expect that Perspective Therapeutics will post -1.01 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, CEO Johan Spoor purchased 47,000 shares of the business’s stock in a transaction dated Wednesday, November 11th. The stock was bought at an average price of $0.81 per share, for a total transaction of $38,070.00. Following the purchase, the chief executive officer owned 106,383 shares of the company’s stock, valued at $86,170.23. The trade was a 79.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Markus Puhlmann acquired 35,000 shares of the stock in a transaction that occurred on Thursday, November 12th. The stock was purchased at an average price of $0.84 per share, for a total transaction of $29,400.00. Following the completion of the purchase, the insider directly owned 178,542 shares in the company, valued at $149,975.28. This trade represents a 24.38% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 151,648 shares of company stock worth $128,314 in the last ninety days. Insiders own 2.99% of the company’s stock.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of CATX. Provenance Wealth Advisors LLC bought a new position in Perspective Therapeutics during the 3rd quarter worth approximately $44,000. Auctus Advisors LLC boosted its stake in shares of Perspective Therapeutics by 83.6% during the third quarter. Auctus Advisors LLC now owns 37,359 shares of the company’s stock valued at $103,000 after purchasing an additional 17,015 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Perspective Therapeutics by 53.1% in the third quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company’s stock worth $168,000 after purchasing an additional 21,150 shares during the last quarter. Quantinno Capital Management LP purchased a new position in shares of Perspective Therapeutics in the first quarter worth $273,000. Finally, Taylor & Morgan Wealth Management LLC increased its stake in shares of Perspective Therapeutics by 127.6% in the second quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company’s stock worth $225,000 after buying an additional 37,000 shares during the period. Hedge funds and other institutional investors own 54.66% of the company’s stock.
Perspective Therapeutics Company Profile
Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.
Recommended Stories
- Five stocks we like better than Perspective Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
